Detection of peripheral HIV-1-specific memory B cells in patients untreated or receiving highly active antiretroviral therapy

AIDS. 2003 Nov 7;17(16):2323-30. doi: 10.1097/00002030-200311070-00006.

Abstract

Objectives: To examine whether polyclonal activation of circulating B cells, in a process that involves CD40-CD40 ligand and cytokine interactions, could induced HIV-1-specific memory B cells to synthesize HIV-1-specific antibodies.

Methods: B cells from 26 HIV-1-infected patients were cultured with a CD40L-transfected cell line plus interleukins 2 and 10 and tested for their secretion of HIV-1- and Toxoplasma gondii-specific antibodies.

Results: In vitro activated B lymphocytes from HIV-1-infected patients secreted anti-HIV-1-specific antibodies. B cells from HIV-1-infected patients as well as those from controls chronically infected by T. gondii synthesized T. gondii-specific antibodies. HIV-1-specific IgG-, IgA- or IgM-secreting B cells represented approximately 1 x 10(-4) to 1 x 10(-5) of total circulating B cells and 1 x 10(-2) to 1 x 10(-3) of immunoglobulin-secreting cells. HIV-1-specific memory B cells were found in 9/9 untreated patients and in 8/17 patients receiving highly active antiretroviral therapy (HAART). The other nine patients showed a normal CD40-CD40L B cell response and six of them produced T. gondii-specific antibody B cells. The follow-up of seven patients indicated that HIV-1-specific memory B cells became undetectable after 8 to 46 months of HAART, whereas T. gondii-specific memory B cells persisted in parasite coinfected patients.

Conclusions: Circulating memory HIV-1-specific B cells were detected in untreated patients and in about half of the patients taking HAART, suggesting that persistent low-level ongoing viral replication is not sufficient to maintain HIV-1-specific memory B cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / therapeutic use
  • Antibody Specificity
  • Antiretroviral Therapy, Highly Active*
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / immunology*
  • CD40 Ligand / immunology
  • Cells, Cultured
  • Chronic Disease
  • HIV Antibodies / biosynthesis
  • HIV Infections / drug therapy
  • HIV Infections / immunology*
  • HIV Infections / virology
  • HIV-1 / immunology*
  • HIV-1 / physiology
  • Humans
  • Immunologic Memory / immunology
  • Lymphocyte Activation / immunology
  • Viral Load
  • Virus Replication

Substances

  • Anti-HIV Agents
  • HIV Antibodies
  • CD40 Ligand